Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 7,800 Shares

Share on StockTwits

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction on Thursday, December 13th. The stock was sold at an average price of $42.66, for a total transaction of $332,748.00. Following the transaction, the chief executive officer now owns 733,285 shares in the company, valued at approximately $31,281,938.10. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Atara Biotherapeutics stock opened at $41.72 on Friday. Atara Biotherapeutics Inc has a 1-year low of $14.50 and a 1-year high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.13) by ($0.16). Analysts expect that Atara Biotherapeutics Inc will post -4.82 earnings per share for the current year.

Several institutional investors have recently modified their holdings of ATRA. Principal Financial Group Inc. purchased a new position in shares of Atara Biotherapeutics during the 1st quarter valued at $214,000. Bank of Montreal Can purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at $180,000. TD Asset Management Inc. lifted its stake in shares of Atara Biotherapeutics by 4.9% during the 2nd quarter. TD Asset Management Inc. now owns 43,089 shares of the biotechnology company’s stock valued at $1,584,000 after buying an additional 2,000 shares in the last quarter. Alps Advisors Inc. lifted its stake in shares of Atara Biotherapeutics by 12.7% during the 2nd quarter. Alps Advisors Inc. now owns 63,333 shares of the biotechnology company’s stock valued at $2,327,000 after buying an additional 7,161 shares in the last quarter. Finally, State of Wisconsin Investment Board lifted its stake in shares of Atara Biotherapeutics by 53.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 41,400 shares of the biotechnology company’s stock valued at $1,521,000 after buying an additional 14,500 shares in the last quarter.

Several research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, November 30th. Finally, BidaskClub upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $47.80.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/2018/12/16/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-7800-shares/3085102.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: How To Calculate Debt-to-Equity Ratio

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.